The formulary process from a risk management perspective

Pharmacotherapy

Volumn 30, Issue 6 PART 2, 2010, Pages

  Raber, Jack H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Formulary; P T; Pharmacy and therapeutics committee; Pharmacy regulation; Pharmacy risk management; REMS; Risk evaluation and mitigation strategies

Indexed keywords

ALVIMOPAN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANABOLIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; CONTRAST MEDIUM; DEXAMETHASONE; DOFETILIDE; DROPERIDOL; FENTANYL; GADOLINIUM; GLITAZONE DERIVATIVE; HEPARINOID; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN ANTAGONIST;

BLACK BOX WARNING; CLINICAL PHARMACY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG INFORMATION; DRUG SAFETY; DRUG USE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HOSPITAL COST; HOSPITAL POLICY; HUMAN; LEGAL LIABILITY; MEDICAID; OFF LABEL DRUG USE; PHARMACIST ATTITUDE; REVIEW; RISK MANAGEMENT;

FORMULARIES, HOSPITAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; RISK MANAGEMENT;

EID: 77954012383     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.pt2.42S     Document Type: Review

References (17)

1. Condition of Participation: Pharmaceutical Services. Fed Regist 1986;51:22042. To be codified at 42 CFR §482.25.
2. Wickline v State of California, 192 Cal App 3d 1630, 239 Cal Rptr 810 (Ct App), cert granted, 727 P 2d 753, 231 Cal. Rptr 560 (1986), review dismissed, cause remanded, 741 P 2d 613, 239 Cal Rptr 805 (1987).
3. Cacciatore GC. Caveats: legal aspects of managed care formulary decisions. J Manag Care Pharm 1996;2:692-5.
4. Labeling. Fed Regist 2006;71(15):13963-4. To be codified at 21 CFR §201.57.
5. Murphy S, Roberts R. "Black box" 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006;117;34-9.
6. Willey ME, Li Z. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling. Pharmacoepidemiol Drug Saf 2004;13:201-6. (Pubitemid 38514833)
7. Generali J. Black box warnings. Available from http://blackboxrx.com. Accessed April 8, 2010.
8. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
9. Taylor Pharmaceuticals. Inapsine (droperidol) package insert. Decatur, IL; 2006.
10. DeMartini L, LeWinter RA, Rubin T. California Department of Public Health hospital oversight. Available from http://www.socalpatientsafety.org/materials/ docs/03-04-2009/10-Cat-CDPH.pdf. Accessed January 11, 2010.
11. Habib AS, Gan TJ. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth 2008;20:35-9.
12. Food and Drug Amendments Act, 21 USC §355(p) (2007).
13. Tyler LS, Cole SW, May JR, et al, for the American Society of Health-System Pharmacists Expert Panel on Formulary Management. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm 2008;65:1272-83.
14. Pfizer Labs. Tikosyn (dofetilide) package insert. New York, NY; 2006.
15. Adolor Corporation. E.A.S.E. program. Exton, PA; 2009.
16. Adolor Corporation. Entereg (alvimopan) package insert. Exton, PA; 2009.
17. Pick AM, Massoomi F, Neff WJ, et al. A safety assessment tool for formulary candidates. Am J Health Syst Pharm 2006;63:1269-72. (Pubitemid 44025092)